Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treatment to reduce new heterotopic ossification lesions and flare-ups in FOP patients. Soleo Health will support patient access and infusion therapy coordination using its expertise in rare diseases. This partnership highlights Soleo's commitment to specialized care for rare conditions and expands its Rare Disease Specialty Pharmacy services.
Regeneron Pharmaceuticals Inc (REGN) holds a market cap of $95.17 billion and has a dividend yield of 0.41% as of Nov 10, 2026, 19:11 WIB. The stock shows a slight 1-day price increase of 0.11%, trading at USD 921.00 on Pluang. Despite the news of Soleo Health partnering to support Regeneron's Pasatru™ treatment, Pluang order activity leans heavily towards selling at 78%.
